Clinical development of IMOJEV®—a recombinant Japanese encephalitis chimeric vaccine (JE-CV)

Bibliography

• Gubler D, Kuno G, Markoff L. In: Fields BN, Knipe DM, Howley PM. Flaviviruses, Japanese encephalitis virus. 530, Walnut Street, Philadelphia, PA 19106, USA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 1185-90
   Google Scholar
• World Health Organization. Japanese Encephalitis vaccines. Wkly Epidemiol Rec 1998;73:337-44
   PubMedGoogle Scholar
• Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992;14:197-221
   PubMed Web of Science ®Google Scholar
• Buescher EL, Scherer WF. Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions. Am J Trop Med Hyg 1959;8:719-22
   PubMed Web of Science ®Google Scholar
• Rosen L. The natural history of Japanese encephalitis virus. Annu Rev Microbiol 1986;40:395-414
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002;267:11-48
   PubMed Web of Science ®Google Scholar
• Solomon T, Ni H, Beasley DW, Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003;77:3091-8
   PubMed Web of Science ®Google Scholar
• Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 1986;67:591-5
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Saini M, Rauthan M, Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 2006;8:92-104
   PubMed Web of Science ®Google Scholar
• Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988;141:3606-10
   PubMed Web of Science ®Google Scholar
• Takegami T, Miyamoto H, Nakamura H, Yasui K. Biological activities of the structural proteins of Japanese encephalitis virus. Acta Virol 1982;26:312-20
   PubMed Web of Science ®Google Scholar
• Hoke CH, Nisalak A, Sangawhipa N, Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319:608-14
   PubMed Web of Science ®Google Scholar
• Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 1996;348:202-3
   PubMed Web of Science ®Google Scholar
• Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 1997;15:1239-43
   PubMed Web of Science ®Google Scholar
• Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991;337:1044
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Nakashima K, Takahashi H, Anaphylaxis to Japanese encephalitis vaccine. Allergy 2001;56:804-5
   PubMed Web of Science ®Google Scholar
• Ni H, Chang GJ, Xie H, Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol 1995;76:409-13
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO, Global Advisory Committee on vaccine safety, 9 – 10 June 2005. Wkly Epidemiol Rec 2005;80:242-3
   PubMedGoogle Scholar
• Bista MB, Banerjee MK, Shin SH, Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001;358:791-5
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005;366:1375-8
   PubMed Web of Science ®Google Scholar
• Sohn YM, Tandan JB, Yoksan S, A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 2008;26:1638-43
   PubMed Web of Science ®Google Scholar
• Tandan JB, Ohrr H, Sohn YM, Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007;25:5041-5
   PubMed Web of Science ®Google Scholar
• Mehta P, Christopher DE, Taylor W, Case study 6: Acambis and Sanofi Pasteur - Japanese encephalitis vaccine development. Bioventures Global Health 2009;52-6
   Google Scholar
• Guy B, Guirakhoo F, Barban V, Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28:632-49
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999;73:3095-101
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005;18:387-94
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Vrati S. IMOJEV®: a yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010;9:1371-84
   PubMed Web of Science ®Google Scholar
• Dean CH, Alarcon JB, Waterston AM, Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVaxTM-JE) in non-human primates. Hum Vaccin 2005;1:106-11
   PubMed Web of Science ®Google Scholar
• Monath TP, Levenbook I, Soike K, Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000;74:1742-51
   PubMed Web of Science ®Google Scholar
• Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. 7, Westferry Circus, Canary Wharf, London, E14 4HB, UK: European Medical Agency, Committee for Medicinal Products for Human Use; 2010. p. 1-14
   Google Scholar
• Note for Guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. 7, Westferry Circus, Canary Wharf, London, E14 4HB, UK: The European agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human use; 2001. p. 1-33
   Google Scholar
• Australian Public Assessment report for Japanese Encephalitis Chimeric Virus. PO Box 100, Woden ACT 2606, Australia: Australian Government, Department of Health and Ageing; 2010. p. 1-77
   Google Scholar
• Beasley DW, Li L, Suderman MT, Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine. Vaccine 2004;22:3722-6
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang ZX, Chambers TJ, Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999;257:363-72
   PubMed Web of Science ®Google Scholar
• Monath TP, Soike K, Levenbook I, Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999;17:1869-82
   PubMed Web of Science ®Google Scholar
• Lobigs M, Larena M, Alsharifi M, Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 2009;83:2436-45
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010;29:1111-17
   PubMed Web of Science ®Google Scholar
• Monath TP, McCarthy K, Bedford P, Clinical proof of principle for ChimeriVaxTM-JE: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002;20:1004-18
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R, Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVaxTM-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188:1213-30
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Ebringer A, Elmes N, Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 2010;6:1038-46
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Marjason J, Bennett S, Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin 2010;6:906-14
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine 2010;28:7993-8000
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Guirakhoo F, Ocran SW, High fidelity of yellow fever virus RNA polymerase. J Virol 2004;78:1032-8
   PubMed Web of Science ®Google Scholar